Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000894594
Ethics application status
Approved
Date submitted
1/07/2024
Date registered
22/07/2024
Date last updated
22/07/2024
Date data sharing statement initially provided
22/07/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Maximising Embedded pharmacists in aGed cAre Medication Advisory Committees (MEGA-MAC): implementing Australia’s new Guiding Principles for Medication Management in Residential Aged Care Facilities using a knowledge broker and national quality improvement collaborative intervention.
Scientific title
Maximising Embedded pharmacists in aGed cAre Medication Advisory Committees (MEGA-MAC): implementing Australia’s new Guiding Principles for Medication Management in Residential Aged Care Facilities using a knowledge broker and national quality improvement collaborative intervention.
Secondary ID [1] 312244 0
Nil
Universal Trial Number (UTN)
Trial acronym
Maximising Embedded pharmacists in aGed cAre Medication Advisory Committees (MEGA-MAC).
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polypharmacy 334030 0
Medication management 334254 0
Clinical governance 334255 0
Medication policy development 334256 0
Condition category
Condition code
Public Health 330794 330794 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This trial will evaluate a multifactorial intervention to implement the Commonwealth of Australia (Department of Health and Aged Care) Guiding Principles for Medication Management in Residential Aged Care Facilities (Guiding Principles) in Australian residential aged care facilities (RACFs).

This is a RACF-level intervention. Each RACF will receive the intervention for nine months. The intervention involves a knowledge broker dyad (pharmacist and Medication Advisory Committee [MAC] representative) who will develop, implement and evaluate RACF-specific local action plans to implement the Guiding Principles. Knowledge brokers are individuals or groups that help to move knowledge from those who create the knowledge to those that use the knowledge. The knowledge broker dyad will be supported by a national quality improvement collaborative, called the MEGA-MAC collaborative.

The knowledge broker dyad will consist of:
* A registered pharmacist working on-site at the RACF. The pharmacist will be responsible for leading the knowledge broker dyad and will spend 4.5 hours per RACF per week on the intervention.
* A healthcare professional MAC representative (chair or member of the MAC) who provides services to the RACF. The MAC representative will spend 1.5 hours per RACF per week supporting the pharmacist to deliver the intervention.

The knowledge broker pharmacist may work at one participating RACF or multiple participating RACFs. In the latter case, the knowledge broker pharmacist may collaborate with a different MAC representative for each RACF, the same MAC representative for all the RACFs the MAC governs, or a mixture of both.

The knowledge broker dyads will be trained to deliver the intervention. Training will involve completing a series of self-paced education modules that will take approximately 4 hours in total. Training will be developed by the Project Management Team and will be made available to the knowledge broker dyads within 4 weeks of commencing the intervention. The education modules will cover topics on medication safety and the quality use of medicines in Australian residential aged care, the Guiding Principles, the MEGA-MAC study design and knowledge translation (e.g. local actions plans, how to be a knowledge broker).

The MEGA-MAC collaborative will act as a real-time clinical network to facilitate sharing of experience and expertise between the knowledge broker dyads at each RACF and support the knowledge broker dyads, RACFs, MACs and aged care provider organisations to implement the Guiding Principles into practice. The MEGA-MAC collaborative will be supported by a panel of clinical experts, implementation scientists and consumer representatives. The MEGA-MAC collaborative will conduct quarterly virtual ‘MEGA-MAC’ meetings (baseline, 3, 6 and 9 months), distribute quarterly ‘MEGA-MAC’ newsletters (baseline, 3, and 6 months), provide expert and peer review feedback on the knowledge broker dyads’ local action plans (baseline, 3 months and at 6 months), and offer ongoing ad-hoc expert and peer support via virtual meetings. ‘MEGA-MAC’ meetings will be approximately one hour in duration and all knowledge broker dyads participating in the intervention will be invited to attend.

Ongoing fidelity of the intervention delivered by the knowledge broker dyads will be monitored using the local action plans, the MEGA-MAC collaborative meetings and monthly meetings with the Project Management Team.
Intervention code [1] 328840 0
Treatment: Other
Comparator / control treatment
The trial will use an interrupted time series design. This design will involve retrospective (pre-intervention: - 6 months, -3 months, baseline) and prospective (post-intervention: 3 months, 6 months and 9 months) data collection. The outcomes from delivering the intervention post-intervention will be compared to pre-intervention.
Control group
Active

Outcomes
Primary outcome [1] 338559 0
Change in RACF-level concordance with the Guiding Principles post-intervention compared to pre-intervention.
Timepoint [1] 338559 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [1] 436438 0
Change in RACF-level concordance with domain one study indicators post-intervention compared to pre-intervention.
Timepoint [1] 436438 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [2] 437011 0
Change in RACF-level concordance with domain two study indicators post-intervention compared to pre-intervention.
Timepoint [2] 437011 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [3] 437012 0
Change in RACF-level concordance with domain three study indicators post-intervention compared to pre-intervention.
Timepoint [3] 437012 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [4] 437013 0
Change in RACF-level concordance with domain four study indicators post-intervention compared to pre-intervention.
Timepoint [4] 437013 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [5] 437014 0
Change in RACF-level concordance with each of the 28 individual indicators post-intervention compared to pre-intervention.
Timepoint [5] 437014 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [6] 437015 0
Change in RACF-level proportion of residents hospitalised post intervention compared to pre-intervention. This outcome will include emergency department presentations and hospital admissions within the last 3 months.
Timepoint [6] 437015 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [7] 437016 0
Change in RACF-level proportion of residents who report ‘excellent’ or ‘good’ quality of life post intervention compared to pre-intervention.
Timepoint [7] 437016 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [8] 437017 0
Change in RACF-level proportion of residents who report ‘excellent’, or ‘good’ consumer experience post intervention compared to pre-intervention.
Timepoint [8] 437017 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [9] 437018 0
Change in RACF-level proportion of medication incidents post intervention compared to pre-intervention.
Timepoint [9] 437018 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [10] 437019 0
Direct costs of the intervention: measurement and valuation of the direct costs of the intervention (e.g. salary costs of the knowledge broker dyad).
Timepoint [10] 437019 0
9 months post intervention commencement.
Secondary outcome [11] 437020 0
Downstream costs of the intervention: measurement and valuation of the downstream costs of the intervention (e.g. staff time preparing for MAC meetings) pre-intervention compared to post-intervention.
Timepoint [11] 437020 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.
Secondary outcome [12] 437021 0
Cost benefits: measurement of the monetised impact of medication incidents and hospitalisations pre-intervention compared to post-intervention.
Timepoint [12] 437021 0
Pre-intervention: -6 months, -3 months, baseline and post-intervention: 3 months, 6 months and 9 months.

Eligibility
Key inclusion criteria
This will be a system-level intervention delivered at the RACF-level. RACFs will be eligible if they have a MAC or commit to establishing a MAC by the commencement of the intervention.

Pharmacists will be eligible if they hold general registration with the Australian Health Practitioner Regulation Agency (AHPRA) as a pharmacist and are willing to commit to the delivery of the intervention.

The health care professional MAC representative will be eligible if they are a MAC chair or another suitable current MAC member, have a health professional background and are willing to commit to the delivery of the intervention.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
This is a RACF-level intervention. This study does not have resident-level exclusion criteria.

RACFs will be ineligible if they don’t have a MAC or don’t commit to establishing a MAC by the commencement of the intervention.

Pharmacists will be ineligible if they do not hold general registration with the AHPRA or are not available to commit to the delivery of the intervention.

The health care professional MAC representative will be ineligible if they do not have a health professional background or are not willing and able to commit to the delivery of the intervention.

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
The study will involve interrupted time series design that will involve retrospective (pre-intervention) and prospective (post-intervention) data collection. Each RACF will act as its own control during the pre-intervention period.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size
Up to 15 RACFs will be recruited across Western Australia, South Australia, New South Wales and Victoria.

Effectiveness analysis
The primary analysis will employ a linear mixed model approach to investigate the effect of commencement of the intervention on the composite primary outcome. It will include treatment period (pre-intervention vs post-intervention) as a fixed, binary factor in the model; study month as a continuous, fixed factor; and individual site as a random effect nested within the random effect of a MAC.

An additional analysis will be presented that is the same as that described above but includes an interaction term between the treatment period and study month factors. We will follow recommendations for presentation of results of trials of this nature, and present both the models with and without the interaction term to allow comparison between the two.

Exploratory analyses to investigate the heterogeneity in treatment effects within sites and MACs will be undertaken by examining best linear unbiased predictions (BLUPs). Multiple imputation will be used to impute missing outcome values, where necessary.

All primary analyses will be conducted using the intention-to-treat (ITT) principle. Per protocol analysis will also be undertaken with the per protocol set including all RACFs without a major protocol deviation. Major protocol deviations may include, but are not limited to, the following:
*Loss of knowledge broker dyad (one or both members of the dyad)
*Incomplete delivery of the intervention (e.g. local action plans, attendance at MEGA-MAC meetings).

Data will be analysed using Stata (StataCorp, College Station, TX), SAS (SAS Institute, Cary, NC) and the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL).

Economic evaluation
A net benefit analysis will be conducted to examine the relative costs and benefits of implementing the intervention.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
15/08/2024
Actual
Date of last participant enrolment
Anticipated
30/09/2024
Actual
Date of last data collection
Anticipated
31/07/2025
Actual
Sample size
Target
15
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 316621 0
Government body
Name [1] 316621 0
Commonwealth of Australia represented by the Department of Health and Aged Care
Country [1] 316621 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 318807 0
University
Name [1] 318807 0
Univeristy of Sydney
Address [1] 318807 0
Country [1] 318807 0
Australia
Secondary sponsor category [2] 319085 0
University
Name [2] 319085 0
Flinders University
Address [2] 319085 0
Country [2] 319085 0
Australia
Secondary sponsor category [3] 319086 0
Other
Name [3] 319086 0
New South Wales Therapeutic Advisory Group Inc.
Address [3] 319086 0
Country [3] 319086 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 315406 0
Monash University Human Research Ethics Committee
Ethics committee address [1] 315406 0
Ethics committee country [1] 315406 0
Australia
Date submitted for ethics approval [1] 315406 0
18/03/2024
Approval date [1] 315406 0
03/05/2024
Ethics approval number [1] 315406 0
42018

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 134606 0
Prof John Simon Bell
Address 134606 0
Monash University, 381 Royal Parade, Parkville, VIC, 3052
Country 134606 0
Australia
Phone 134606 0
+61 03 9903 9533
Fax 134606 0
Email 134606 0
Simon.Bell2@monash.edu
Contact person for public queries
Name 134607 0
Ms Brooke Blakeley
Address 134607 0
Monash University, 381 Royal Parade, Parkville, VIC, 3052
Country 134607 0
Australia
Phone 134607 0
+61 03 9903 9035
Fax 134607 0
Email 134607 0
brooke.blakeley@monash.edu
Contact person for scientific queries
Name 134608 0
Dr Amanda Cross
Address 134608 0
Monash University, 381 Royal Parade, Parkville, VIC, 3052
Country 134608 0
Australia
Phone 134608 0
+61 03 9903 9471
Fax 134608 0
Email 134608 0
amanda.cross@monash.edu

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
This is a RACF-level intervention and no individual participant data will be collected during the trial.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.